SI figure 6. Impact of CO-1686, erlotinib and afatinib administration on mouse body weight. Mice bearing A431 (EGFR WT) tumors were dosed with CO-1686, erlotinib or afatinib at the doses and schedules indicated. Data plotted as average body weight ±SEM measured over time. *P < 0.01 comparing day 22 body-weight to control.